First Time Loading...
S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 9.35 CHF 0.11% Market Closed
Updated: May 17, 2024

Santhera Pharmaceuticals Holding AG
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Santhera Pharmaceuticals Holding AG
Research & Development Peer Comparison

Comparables:
ADCT
ACIU
CRSP
BSLN
IDIA

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Research & Development
-CHf18.7m
CAGR 3-Years
18%
CAGR 5-Years
13%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Research & Development
-$127.1m
CAGR 3-Years
3%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Research & Development
-CHf54.6m
CAGR 3-Years
3%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Research & Development
-$363.6m
CAGR 3-Years
-6%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Research & Development
-CHf77.9m
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
-4%
Idorsia Ltd
SIX:IDIA
Research & Development
-CHf368.3m
CAGR 3-Years
4%
CAGR 5-Years
-22%
CAGR 10-Years
N/A

See Also

What is Santhera Pharmaceuticals Holding AG's Research & Development?
Research & Development
-18.7m CHF

Based on the financial report for Dec 31, 2023, Santhera Pharmaceuticals Holding AG's Research & Development amounts to -18.7m CHF.

What is Santhera Pharmaceuticals Holding AG's Research & Development growth rate?
Research & Development CAGR 5Y
13%

Over the last year, the Research & Development growth was 39%. The average annual Research & Development growth rates for Santhera Pharmaceuticals Holding AG have been 18% over the past three years , 13% over the past five years .